

NEUROCRINE BIOSCIENCES INC

Form 4

May 18, 2006

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
HAWRAN PAUL W

2. Issuer Name **and** Ticker or Trading
Symbol
**NEUROCRINE BIOSCIENCES
INC [NBIX]**

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)
**NEUROCRINE BIOSCIENCES,
INC., 12790 EL CAMINO REAL**

3. Date of Earliest Transaction
(Month/Day/Year)
05/17/2006

____ Director ____ 10% Owner
☒ Officer (give title below) ____ Other (specify below)
Executive VP and CFO

(Street)
SAN DIEGO, CA 92130

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D) Price			
Common Stock	05/17/2006		S <u>(1)</u>		2,598	D \$ 19.93	244,883	D	
Common Stock	05/17/2006		S <u>(1)</u>		3,500	D \$ 19.85	241,383	D	
Common Stock	05/17/2006		S <u>(1)</u>		2,949	D \$ 19.86	238,434	D	
Common Stock	05/17/2006		S <u>(1)</u>		500	D \$ 19.87	237,934	D	
Common Stock	05/17/2006		S <u>(1)</u>		78	D \$ 19.89	237,856	D	

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

Common Stock	05/17/2006	<u>S(1)</u>	200	D	\$ 19.88	237,656	D	
Common Stock	05/17/2006	<u>S(1)</u>	3,273	D	\$ 19.9	234,383	D	
Common Stock	05/17/2006	<u>S(1)</u>	1,400	D	\$ 20.5	232,983	D	
Common Stock	05/17/2006	<u>S(1)</u>	300	D	\$ 20.6	232,683	D	
Common Stock	05/17/2006	<u>S(1)</u>	2,461	D	\$ 20.1	230,222	D	
Common Stock	05/17/2006	<u>S(1)</u>	200	D	\$ 20.11	230,022	D	
Common Stock	05/17/2006	<u>S(1)</u>	48	D	\$ 20.14	229,974	D	
Common Stock	05/17/2006	<u>S(1)</u>	830	D	\$ 20.12	229,144	D	
Common Stock	05/17/2006	<u>S(1)</u>	1,000	D	\$ 20.14	228,144	D	
Common Stock	05/17/2006	<u>S(1)</u>	31,144	D	\$ 19.68	197,000	I	By Limited Liability Company
Common Stock	05/17/2006	<u>S(1)</u>	5,000	D	\$ 19.66	192,000	I	By Limited Liability Company
Common Stock	05/17/2006	<u>S(1)</u>	22,500	D	\$ 19.7	169,500	I	By Limited Liability Company
Common Stock	05/17/2006	<u>S(1)</u>	20,000	D	\$ 19.8	149,500	I	By Limited Liability Company
Common Stock	05/17/2006	<u>S(1)</u>	7,500	D	\$ 19.85	142,000	I	By Limited Liability Company
Common Stock	05/17/2006	<u>S(1)</u>	10,000	D	\$ 19.97	132,000	I	By Limited Liability Company

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
HAWRAN PAUL W NEUROCRINE BIOSCIENCES, INC. 12790 EL CAMINO REAL SAN DIEGO, CA 92130	Executive VP and CFO

Signatures

Margaret E. Valeur-Jensen, By Power of Attorney 05/18/2006

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The shares were sold by the Reporting Person's broker following a margin call, without instruction by the Reporting Person

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.